News and Policies
IPR protection fuels R&D of innovative drugs for Pudong-based pharma
Updated: May 19, 2025
english.pudong.gov.cn
Print
Share - WeChat
The long and costly R&D cycles of innovative drugs make intellectual property rights (IPR) protection paramount, according to Naoto Oizumi, legal senior patent counsel at Takeda China — a multinational pharmaceutical corporation based in Shanghai's Pudong New Area.
China's continuous efforts to safeguard IPR have solidified Takeda's confidence in investing in Shanghai. From 2015 to 2020, the pharma giant spent 1.5 billion yuan ($208 million) in new drugs R&D, bringing 15 innovative products to the Chinese market from 2020 to 2024.
